Erik serves as CEO at AM-Pharma from 2011 and has over 25 years’ experience.

Erik is Chairman of Step Pharma and co-founder and previous (executive) Chairman of Lava Therapeutics (NASDAQ: LVTX), co-founder and previous (executive) Chairman of Heatmatrix Group (sold to BosNieuwkerk) and was board member of Lead Pharma and the Dutch biotechnology organization.

As Senior Executive at Organon he was responsible for global biotechnology business development. Prior to joining Organon, Erik worked in business and corporate development at the biotechnology company IsoTis (SWX/Euronext: ISON – sold to Integra Lifesciences), and as a Management Consultant at Arthur D. Little. Erik has been involved in the execution of over 20 transactions and partnerships, including a $600M alliance with Pfizer, $290M partnership with Kyowa Kirin and raised close to €500M in equity and debt financing for biotechnology companies from seed through IPO.

Erik holds a Master’s degree in Chemistry from the University of Utrecht (NL) and an MBA from Manchester Business School (UK).


Our board of directors is made up of seasoned industry investors and executives who provide their leadership and experience as we progress our promising pipeline into the clinic.